UK markets open in 6 hours 53 minutes

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
20.09-0.56 (-2.71%)
At close: 04:00PM EST
20.01 -0.08 (-0.40%)
After hours: 05:18PM EST

Alector, Inc.

131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States
415 231 5660
http://www.alector.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees185

Key executives

NameTitlePayExercisedYear born
Dr. Tillman Ulf Gerngross Ph.D.Co-Founder & Chairman60kN/A1964
Dr. Arnon RosenthalCo-Founder, CEO & Director566.02kN/A1956
Mr. Calvin YuVP of Fin.370.87k603.64k1976
Dr. Robert Paul M.D., Ph.D.Advisor568.5k495.09k1968
Dr. Robert S. KingChief Devel. Officer556.21kN/A1963
Dr. Shehnaaz Suliman M.B.A., M.D., M.Phil.Advisor677.76kN/A1972
Ms. Linda M. RubinsteinInterim CFO, Principal Financial Officer & Principal Accounting OfficerN/AN/A1967
Michelle CorralVP of Communications & Investor RelationsN/AN/AN/A
Mr. Brian Sander J.D., Ph.D.Gen. CounselN/AN/AN/A
Erica JeffersonVP of Communications & Public AffairsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Corporate governance

Alector, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.